JP2004505087A5 - - Google Patents

Download PDF

Info

Publication number
JP2004505087A5
JP2004505087A5 JP2002515900A JP2002515900A JP2004505087A5 JP 2004505087 A5 JP2004505087 A5 JP 2004505087A5 JP 2002515900 A JP2002515900 A JP 2002515900A JP 2002515900 A JP2002515900 A JP 2002515900A JP 2004505087 A5 JP2004505087 A5 JP 2004505087A5
Authority
JP
Japan
Prior art keywords
slurry
give
solution
ethyl
ethyl alcohol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002515900A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004505087A (ja
Filing date
Publication date
Priority claimed from GB0018656A external-priority patent/GB0018656D0/en
Priority claimed from GB0106464A external-priority patent/GB0106464D0/en
Application filed filed Critical
Priority claimed from PCT/IB2001/001280 external-priority patent/WO2002010171A1/en
Publication of JP2004505087A publication Critical patent/JP2004505087A/ja
Publication of JP2004505087A5 publication Critical patent/JP2004505087A5/ja
Pending legal-status Critical Current

Links

JP2002515900A 2000-07-28 2001-07-18 結晶性治療剤 Pending JP2004505087A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0018656A GB0018656D0 (en) 2000-07-28 2000-07-28 Pharmaceutically active compounds
GB0106464A GB0106464D0 (en) 2001-03-15 2001-03-15 Crystalline therapeutic agent
PCT/IB2001/001280 WO2002010171A1 (en) 2000-07-28 2001-07-18 Crystalline therapeutic agent

Publications (2)

Publication Number Publication Date
JP2004505087A JP2004505087A (ja) 2004-02-19
JP2004505087A5 true JP2004505087A5 (enExample) 2007-11-08

Family

ID=26244756

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002515900A Pending JP2004505087A (ja) 2000-07-28 2001-07-18 結晶性治療剤

Country Status (45)

Country Link
EP (1) EP1305314B1 (enExample)
JP (1) JP2004505087A (enExample)
KR (1) KR100457937B1 (enExample)
CN (1) CN1207297C (enExample)
AP (1) AP1400A (enExample)
AR (1) AR032628A1 (enExample)
AT (1) ATE286901T1 (enExample)
AU (2) AU2001272690B2 (enExample)
BG (1) BG107266A (enExample)
BR (1) BR0112734A (enExample)
CA (1) CA2417264C (enExample)
CZ (1) CZ2003126A3 (enExample)
DE (1) DE60108398T2 (enExample)
DO (1) DOP2001000217A (enExample)
DZ (1) DZ3364A1 (enExample)
EA (1) EA004681B1 (enExample)
EC (1) ECSP034454A (enExample)
EE (1) EE200300045A (enExample)
ES (1) ES2231521T3 (enExample)
GE (1) GEP20053494B (enExample)
HR (1) HRP20030061A2 (enExample)
HU (1) HUP0302982A3 (enExample)
IL (1) IL153226A0 (enExample)
IN (1) IN2002MU01649A (enExample)
IS (1) IS6626A (enExample)
MA (1) MA26931A1 (enExample)
MX (1) MX233602B (enExample)
MY (1) MY117831A (enExample)
NO (1) NO324220B1 (enExample)
NZ (1) NZ523226A (enExample)
OA (1) OA12337A (enExample)
PA (1) PA8523501A1 (enExample)
PE (1) PE20020277A1 (enExample)
PH (1) PH12001001922B1 (enExample)
PL (1) PL365133A1 (enExample)
PT (1) PT1305314E (enExample)
SK (1) SK572003A3 (enExample)
SV (1) SV2001000570A (enExample)
TN (1) TNSN01112A1 (enExample)
TW (1) TWI285643B (enExample)
UA (1) UA72631C2 (enExample)
UY (1) UY26854A1 (enExample)
WO (1) WO2002010171A1 (enExample)
YU (1) YU4703A (enExample)
ZA (1) ZA200301457B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004072079A1 (en) * 2003-02-11 2004-08-26 Pfizer Limited Hydrated and anhydrous sildenafil hemi-citrate compound
EA008596B1 (ru) 2003-04-29 2007-06-29 Пфайзер Инк. 5,7-ДИАМИНОПИРАЗОЛО[4,3-d]ПИРИМИДИНЫ, ПОЛЕЗНЫЕ ПРИ ЛЕЧЕНИИ ГИПЕРТЕНЗИИ
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
DK1742950T3 (da) 2004-04-07 2009-03-16 Pfizer Ltd Pyrazolo-[4,3-D]-pyrimidiner
CA2608018C (en) 2005-05-12 2010-07-13 Pfizer Inc. Anhydrous crystalline forms of n-[1-(2-ethoxyethyl)-5-(n-ethyl-n-methylamino)-7-(4-methylpyridin-2-yl-amino)-1h-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1371647B1 (en) * 1998-04-20 2005-07-13 Pfizer Inc. Pyridine-3-carboxylic acid derivatives and their use as intermediates
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them

Similar Documents

Publication Publication Date Title
JP2005179362A5 (enExample)
CA2408914A1 (en) Novel triazolo pyrimidine compounds
JP2008510770A5 (enExample)
JP2010521514A5 (enExample)
JP2023534131A5 (enExample)
JP4588446B2 (ja) ロスバスタチンのカルシウム塩の製造法
JP2007520453A5 (enExample)
JP2009533369A5 (enExample)
JP2008518890A5 (enExample)
JP2007514638A5 (enExample)
WO2004020438A2 (en) Novel processes and intermediates for preparing triazolo-pyridines
JPWO2021220648A5 (enExample)
CN103936681B (zh) 2-氨基-4,6-二氯-5-甲酰胺基嘧啶的制备方法
EP2222375A1 (en) Improved process for the manufacture of anagrelide hidrochloride monhydrate
CN102796036B (zh) 一种阿托伐他汀钙的制备方法
JP2003234133A5 (enExample)
JP2015500805A5 (enExample)
CA2425561A1 (en) Process to prepare 1,4-dihydropyridine intermediates and derivatives thereof
CN103483261A (zh) 1-取代苯基-3-羧甲基-5-吡唑啉酮的制备方法
CN101522680A (zh) 制备阿巴卡韦的方法
HRP20161186T1 (hr) Soli heterociklamidno supstituiranih imidazola sa sulfonskim kiselinama
CN100532389C (zh) 改进的2-取代腺苷的合成
KR20180105450A (ko) 피마살탄 콜린염 및 이의 수화물의 제조방법
CA2366521A1 (en) A new and efficient process for the preparation of lamotrigine and related 3,5-diamino-6-substituted-1,2,4-triazines
JPH0149706B2 (enExample)